Taking into account phase I and phase II clinical trials of patients with colorectal and ovarian cancer treated with GM102, it was shown that in the case of colorectal cancer the number of blood monocytes CD69+ increases, while the number of CD69+ activated-regulatory T cells decreases (189). This evidence concerns the gene CD69 and colorectal cancer.